Bhaskar Bhattacharya

Dr. Bhaskar Bhattacharya serves as a Research Associate in Therapeutic Science Research at the University of Glasgow, where he investigates molecular mechanisms of drug resistance in gastrointestinal cancers. His position within the university's research infrastructure focuses on translational oncology with emphasis on metabolic adaptations in tumor cells.

Research interests center on cancer drug resistance mediated through metabolic reprogramming (particularly glycolysis and the Warburg effect), mitochondrial DNA mutations, and tumor microenvironment interactions. His work spans hepatocellular, colorectal, and gastric cancers, examining how cellular adaptations confer resistance to targeted therapies like PI3K/mTOR inhibitors and conventional chemotherapeutics including 5-Fluorouracil. Key investigations include the role of CTPS2 expression in chemoresistance and kinase signaling pathways in therapeutic failure.

Analysis of his 10 publications (2003-2021) reveals a consistent trajectory from vascular pharmacology to cancer metabolism research. Early work (2003-2005) established expertise in signal transduction, while the core output (2011-2017) details metabolic resistance mechanisms across multiple gastrointestinal cancers. Recent publications (2021) extend this to microenvironmental influences on hepatocellular carcinoma drug sensitivity, demonstrating enduring focus on translational relevance.

Scientific awards are not listed in the available information.

As a research-focused academic, Dr. Bhattacharya's role emphasizes independent investigation rather than student supervision. His publication record indicates sustained research activity likely supported by project grants, though specific funding details aren't provided. Collaborative opportunities exist through the University of Glasgow's research ecosystem, particularly in cancer metabolism and therapeutic resistance fields. The absence of a named laboratory suggests integration within existing departmental research groups rather than independent lab leadership.